Advanced Gastric Cancer
Conditions
Interventions
Nab paclitaxel(80mg/m2 day1,8,15) every 4 weeks
Sponsors
Teikyo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who provided written informed consent. 2.Patients with gastric cancer by histological or cytological examination. 3.Patients with prior on chemothrapy. (including recurrence within 6 months after last adjuvant chemotherapy) 4.More than 2 weeks last chemotherapy 5.ECOG performance status<=2 6.Patients with adequately maintained organ functions and fulfilling the following conditions within 7 days before registration WBC count more than 3,000/mm3 Neutrophils count more than 1,200/mm3 Hemoglobin more than 8.0 g/dl Platelet count more than 75,000/mm3 Serum bilirubin level less than 2.0mg/dl AST and ALT less than 100 IU/l 20 years old or more Patients expected to survive for 90 more than days
Exclusion criteria
Exclusion criteria: 1.History of serious drug hypersensitivity 2.Any other serious illness or medical conditions including interstitial pneumonia or pulmonary fibrosis, renal failure, liver failure,cerebrovascular disordar or Uncontrolled diabates 3.Active infection or fever suspicious of infection. 4.Surgical procedure within 4 weeks before registration 5.Uncontrolled unstable angina, congestive heart failure, myocardial infarction or ventricular arrhythmia 6.History of mental disorder, central nerve disorder. 7.Pregnant women, nursing mothers 8.Patients who were considered by the primary care physician to be inappropriate for this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and grade of Adverse Event, Response Rate,Over all Survival | — |
Countries
Japan
Contacts
Public ContactRyoji Fukushima
Teikyo University School of Medicine Surgery
Outcome results
None listed